Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents

开发针对多重耐药高威胁细菌制剂的创新疗法的中心

基本信息

  • 批准号:
    10613883
  • 负责人:
  • 金额:
    $ 652.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-05-01 至 2024-04-30
  • 项目状态:
    已结题

项目摘要

An epidemic of multidrug-resistant (MDR) bacterial infections plagues US and global health care, and with few new drugs making it to market from an improving but still diminished pipeline, there is an unmet medical need for new therapeutics to treat clinically important high-threat multidrug-resistant infections. High-threat agents comprise Gram negative (GN) and Gram positive (GP) ESKAPE pathogens including Carbapenem-resistant Enterobacteriaceae (CRE), MRSA and multidrug- and extremely drug-resistant Mycobacterium tuberculosis and nontuberculous Mycobacteria (NTM). Our CETR hypothesis postulates that an enterprise-style Center comprised of world-class academic and biopharma investigators with innovative and well-established drug discovery platforms focused on clinically validated and novel targets, promising Leads, and innovative approaches for new compound discovery will serve as an engine to develop selected optimized Leads and Preclinical Development Candidates (PDCs) against high-threat MDR GP and GN bacteria. We propose to: target clinically-successful bacterial targets by exploring novel classes of compounds against RNA polymerase and separately use drug 'repositioning' as a novel high-probability-to-succeed drug discovery strategy against NTMs; characterize novel compounds against key enzymes of mycolic acid biosynthesis in M. tuberculosis; and exploit untapped environmentally-derived novel peptidic compound libraries as a rich source for new antibiotics. Our approach builds upon and refines our current successful CETR model. Critical factors for success include the enterprise-style approach to drug discovery/development, the strength of Project Leaders with robust drug discovery programs and partnerships with biopharma, a highly integrated matrix of mature drug discovery support cores with experienced Core directors, strong central leadership, and outstanding infrastructure with the Rutgers Regional Biocontainment Lab. Collectively, these components comprise a CETR enterprise that will streamline the discovery and advancement of compounds through the optimization process toward PDCs by facilitating critical "go, no-go" decisions. The overall program will be guided by an accomplished researcher, administrator, and current CETR leader in drug discovery, a Scientific Advisory Committee well versed in drug development, and a solid operations and management team that is experienced in large translational research programs resulting in IP and licensing to develop clinical products.
多重耐药 (MDR) 细菌感染的流行困扰着美国和全球的医疗保健,而且几乎没有新药从不断改善但仍然减少的管道中推向市场,因此对治疗临床上重要的高威胁多重耐药感染的新疗法的医疗需求尚未得到满足。高威胁病原体包括革兰氏阴性 (GN) 和革兰氏阳性 (GP) ESKAPE 病原体,包括碳青霉烯类耐药肠杆菌 (CRE)、MRSA 以及多重耐药和极度耐药结核分枝杆菌和非结核分枝杆菌 (NTM)。我们的 CETR 假设假设,一个由世界一流的学术和生物制药研究人员组成的企业式中心,拥有创新和完善的药物发现平台,专注于临床验证和新颖的靶点、有前途的先导化合物和新化合物发现的创新方法,将作为开发针对高威胁 MDR GP 和 GN 细菌的精选优化先导化合物和临床前开发候选物 (PDC) 的引擎。我们建议:通过探索针对 RNA 聚合酶的新型化合物来瞄准临床上成功的细菌靶标,并单独使用药物“重新定位”作为针对 NTM 的新型高成功率药物发现策略;表征针对结核分枝杆菌酸生物合成关键酶的新型化合物;并利用未开发的环境衍生新型肽化合物库作为新型抗生素的丰富来源。我们的方法建立在我们当前成功的 CETR 模型的基础上并对其进行了改进。成功的关键因素包括企业式的药物发现/开发方法、项目领导者的实力、强大的药物发现计划以及与生物制药的合作伙伴关系、由经验丰富的核心董事组成的成熟药物发现支持核心的高度集成矩阵、强大的中央领导力以及罗格斯地区生物防护实验室的出色基础设施。总的来说,这些组件构成了一个 CETR 企业,该企业将通过促进关键的“进行、不进行”决策,通过针对 PDC 的优化过程来简化化合物的发现和开发。整个计划将由一位卓有成就的研究员、管理人员和当前 CETR 药物发现领导者、精通药物开发的科学咨询委员会以及在大型转化研究项目中经验丰富的运营和管理团队指导,从而获得知识产权和开发临床产品的许可。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mycobacterium tuberculosis KasA as a drug target: Structure-based inhibitor design.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David S Perlin其他文献

Worldwide emergence of fluconazole-resistant emCandida parapsilosis/em: current framework and future research roadmap
全球氟康唑耐药近平滑念珠菌的出现:当前框架和未来研究路线图
  • DOI:
    10.1016/s2666-5247(23)00067-8
  • 发表时间:
    2023-06-01
  • 期刊:
  • 影响因子:
    20.400
  • 作者:
    Farnaz Daneshnia;João N de Almeida Júnior;Macit Ilkit;Lisa Lombardi;Austin M Perry;Marilyn Gao;Clarissa J Nobile;Matthias Egger;David S Perlin;Bing Zhai;Tobias M Hohl;Toni Gabaldón;Arnaldo Lopes Colombo;Martin Hoenigl;Amir Arastehfar
  • 通讯作者:
    Amir Arastehfar

David S Perlin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David S Perlin', 18)}}的其他基金

Accelerated development of advanced leads against SARS-CoV-2 and other pandemic viruses
加速开发针对 SARS-CoV-2 和其他大流行病毒的先进先导药物
  • 批准号:
    10513922
  • 财政年份:
    2022
  • 资助金额:
    $ 652.13万
  • 项目类别:
Metropolitan AntiViral Drug Accelerator
大都会抗病毒药物加速器
  • 批准号:
    10513913
  • 财政年份:
    2022
  • 资助金额:
    $ 652.13万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10513914
  • 财政年份:
    2022
  • 资助金额:
    $ 652.13万
  • 项目类别:
Animal Model Core
动物模型核心
  • 批准号:
    10513920
  • 财政年份:
    2022
  • 资助金额:
    $ 652.13万
  • 项目类别:
A CETR-based partnership accelerator for rapid drug development targeting SARS-CoV-2 and pan-CoVs
基于 CETR 的合作加速器,用于针对 SARS-CoV-2 和泛冠状病毒的快速药物开发
  • 批准号:
    10187269
  • 财政年份:
    2020
  • 资助金额:
    $ 652.13万
  • 项目类别:
Critical Factors Influencing Echinocandin Resistance in Candidaglabrata
影响光滑念珠菌棘白菌素耐药性的关键因素
  • 批准号:
    10451830
  • 财政年份:
    2019
  • 资助金额:
    $ 652.13万
  • 项目类别:
Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents
开发针对多重耐药高威胁细菌制剂的创新疗法的中心
  • 批准号:
    10394984
  • 财政年份:
    2019
  • 资助金额:
    $ 652.13万
  • 项目类别:
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negativebacterial infections
针对多重耐药革兰氏阴性细菌感染的新型双特异性免疫预防剂
  • 批准号:
    10380759
  • 财政年份:
    2019
  • 资助金额:
    $ 652.13万
  • 项目类别:
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negative bacterial infections
针对多重耐药革兰氏阴性细菌感染的新型双特异性免疫预防剂
  • 批准号:
    9898899
  • 财政年份:
    2019
  • 资助金额:
    $ 652.13万
  • 项目类别:
Critical Factors Influencing Echinocandin Resistance in Candidaglabrata
影响光滑念珠菌棘白菌素耐药性的关键因素
  • 批准号:
    10215271
  • 财政年份:
    2019
  • 资助金额:
    $ 652.13万
  • 项目类别:

相似海外基金

EXCESS: The role of excess topography and peak ground acceleration on earthquake-preconditioning of landslides
过量:过量地形和峰值地面加速度对滑坡地震预处理的作用
  • 批准号:
    NE/Y000080/1
  • 财政年份:
    2024
  • 资助金额:
    $ 652.13万
  • 项目类别:
    Research Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328975
  • 财政年份:
    2024
  • 资助金额:
    $ 652.13万
  • 项目类别:
    Continuing Grant
SHINE: Origin and Evolution of Compressible Fluctuations in the Solar Wind and Their Role in Solar Wind Heating and Acceleration
SHINE:太阳风可压缩脉动的起源和演化及其在太阳风加热和加速中的作用
  • 批准号:
    2400967
  • 财政年份:
    2024
  • 资助金额:
    $ 652.13万
  • 项目类别:
    Standard Grant
Market Entry Acceleration of the Murb Wind Turbine into Remote Telecoms Power
默布风力涡轮机加速进入远程电信电力市场
  • 批准号:
    10112700
  • 财政年份:
    2024
  • 资助金额:
    $ 652.13万
  • 项目类别:
    Collaborative R&D
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328973
  • 财政年份:
    2024
  • 资助金额:
    $ 652.13万
  • 项目类别:
    Continuing Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328972
  • 财政年份:
    2024
  • 资助金额:
    $ 652.13万
  • 项目类别:
    Continuing Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328974
  • 财政年份:
    2024
  • 资助金额:
    $ 652.13万
  • 项目类别:
    Continuing Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
  • 批准号:
    2332916
  • 财政年份:
    2024
  • 资助金额:
    $ 652.13万
  • 项目类别:
    Standard Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
  • 批准号:
    2332917
  • 财政年份:
    2024
  • 资助金额:
    $ 652.13万
  • 项目类别:
    Standard Grant
Study of the Particle Acceleration and Transport in PWN through X-ray Spectro-polarimetry and GeV Gamma-ray Observtions
通过 X 射线光谱偏振法和 GeV 伽马射线观测研究 PWN 中的粒子加速和输运
  • 批准号:
    23H01186
  • 财政年份:
    2023
  • 资助金额:
    $ 652.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了